Next Arc Research

Not logged in? You're viewing the Free tier. Join for free or log in to access your membership content.
Disclaimer: This content is for informational and educational purposes only and should not be construed as financial or investment advice. Always do your own research and consult a licensed financial advisor before making investment decisions.
Disclosure: The author holds a long position in SDGR.
← Back to Free Index

SDGR

Analysis as of: 2026-04-07
Schrödinger, Inc.
Schrödinger sells molecular modeling and discovery workflow software to pharma and other customers, and also applies the same platform to collaborations and internal drug programs.
ai biotech enterprise healthcare software
On Yahoo Finance ...
Jump to: Summary • Analysis • Opportunity • Risk • Trends • LE Structure • Third Party Analyst Consensus

Summary

Workflow Moat With Partnered Upside
This looks like a software-led recovery story with clinical optionality, not a pure biotech bet. If hosted contracts clean up revenue quality and even one internal program is credibly partnered, the equity can rerate materially without requiring heroic assumptions.

Analysis

Thesis
Schrödinger is a transition-era compounder: if it converts its embedded discovery tools into a hosted workflow system with durable ACV growth, while partnering rather than fully funding pipeline assets, the stock can rerate from a muddled software-biotech hybrid into a cleaner software-led platform with option value.
Last Economy Alignment
Cheaper compute and better AI make simulation-heavy discovery workflows more valuable, and Schrödinger already sits inside those workflows. It is helped by AI, but it does not own the compute stack and still faces internalization and clinical-proof risk.
Upgrade to Allocator to also access: Thesis Critique

Opportunity Outlook

Average Implied 5-Year Multiple
3.6x (from 5 most recent analyses)
Reasoning
The upside case is not that Schrödinger becomes a giant biotech winner; it is that the business mix gets cleaner. If hosted contracts make software revenue more visible, enterprise workflows deepen, and therapeutics upside is financed through partners, investors can pay a better multiple for a steadier software core while still giving credit to milestone and royalty optionality. The ceiling is real because pharma adoption is slow and the company still needs proof that new modules and clinical assets matter.
Upgrade to Allocator to also access: Simplified Opportunity Explanation

Risk Assessment

Overall Risk Summary
The main risk is not near-term liquidity; it is proof transfer. Schrödinger must show that its workflow position can keep pricing power as AI gets cheaper, that hosted migration lifts visibility without masking weak demand, and that clinical assets are partnered or validated before they become a capital drag. The business is attractive when software and optionality reinforce each other; it is vulnerable if software stays merely useful while therapeutics remain unproven.
Upgrade to Allocator to also access: Tech Maturity Risk Score, Adoption Timing Risk Score, Moat Strength Risk Score, Capital Needs Risk Score, Regulatory Risk Score, Execution Risk Score, Concentration Risk Score, Unit Economics Risk Score, Valuation Risk Score, Macro Sensitivity Risk Score

Last Economy Structure

AI Industrial Score
0.55
It sits inside drug-discovery workflows where teams store data, run simulations, and make decisions, so cheaper AI and compute can make the product more useful. The risk is that big pharma builds more in-house tools or cheap agents reduce the value of that workflow position before Schrödinger turns it into stronger pricing.
Upgrade to Reader to also access: Score Decomposition, Confidence Level
Upgrade to Allocator to also access: Obsolescence Vectors, Pricing Fragility
Upgrade to Reader to also access: Constraint Benefit Score, Obsolescence Risk Score

Third Party Analyst Consensus

12-Month Price Target
$21.13
Upgrade to Reader to also access: Bull Case, Base Case, Bear Case